United States
Print page content Print
Increase text size Decrease text size
Text Size

UltraChoice®8

Clostridium Chauvoei-Septicum-Haemolyticum-Novyi-Sordellii-Perfringens Types C and D Bacterin-Toxoid

ultrachoice 8

For use in healthy cattle and sheep as an aid in preventing blackleg caused by Clostridium chauvoei; malignant edema caused by Cl. septicum; bacillary hemoglobinuria caused by CI. haemolyticum; black disease caused by Cl. novyi; gas-gangrene caused by Cl. sordellii; and enterotoxemia and enteritis caused by Cl. perfringens Types B, C and D.  Although Cl. perfringens Type B is not a significant problem in North America, immunity is provided by the beta toxoid of Type C and the epsilon toxoid of Type D.

Collapse All
  • Uses

    Aids in the prevention of diseases caused by the clostridial agents indicated above.

    Key Features

    • Helps provide protection in a tissue-friendly 2mL dose against eight major clostridial diseases (including diseases caused by CI. haemolyticum and CI. perfringens  Types B, C and D), which continue to be of economic importance in cattle. Clostridium bacteria are universally present and product potent toxins that can result in rapid death of otherwise healthy animals.
    • No age restrictions on use.
    • Subcutaneous (SC) dose is 2mL followed by a second dose given four to six weeks later. Annual revaccination with a single dose is recommended.
    • For CI. haemolyticum, repeat the dose every six months in animals subject to re-exposure.
  • Precautions

    Store at 2° - 7°C. Do not freeze. Use entire contents when first opened. Do not vaccinate within 21 days before slaughter. Contains formalin as a preservative.  Temporary local swelling at injection site may occur after administration. Field reports indicate that a transient reduction in milk production may occur following vaccination.  As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.